呼吸道合胞病毒疫苗及中和抗体研究进展
作者:
作者单位:

南京医科大学基础医学院病理学系,国家卫健委抗体技术重点实验室,江苏 南京 211166

作者简介:

通讯作者:

中图分类号:

R392.11

基金项目:

南京医科大学国家疫苗研发创新平台项目


Research progresses of vaccine and neutralizing antibody of respiratory syncytial virus
Author:
Affiliation:

Department of Pathology,National Health Commission Key Laboratory of Antibody Techniques,School of Basic Medical Sciences,Nanjing Medical University,Nanjing 211166 ,China

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    呼吸道合胞病毒(respiratory syncytial virus,RSV)主要引起儿童急性下呼吸道感染(acute lower respiratory tract infection,ALRTI),而ALRTI是导致全球儿童死亡的主要原因。目前临床上针对RSV主要还是以对症治疗为主,特异性治疗药物相对较少。因此,RSV疫苗或抗体药物的研发迫切而重要。现阶段,仅有两款RSV疫苗(Abrysvo和Arexvy)和两款RSV单克隆抗体[帕丽珠单抗(Palivizumab)和尼斯维单抗(Nirsevimab)]上市,在特定的人群中均展示出了较好的临床疗效。文章针对近年来RSV主要疫苗类型及中和抗体的研究进展进行综述,希望可为RSV的预防和治疗提供参考。

    Abstract:

    Respiratory syncytial virus(RSV)mainly causes acute lower respiratory tract infections(ALRTI)in children,which is the main cause of death among children worldwide. At present,symptomatic treatment is the main treatment for RSV in clinical practice,while specific therapeutic drugs are relatively few. Therefore,the research and development of RSV vaccine or antibody drug is urgent and important. At the present stage,two RSV vaccines(Abrysvo and Arexvy)and two RSV monoclonal antibodies (Palivizumab and Nirsevimab)have been released to market,all of which showed good clinical efficacy in specific populations. In this review,the research progress of main vaccine types and neutralizing antibodies of RSV in recent years was reviewed,hoping to provide reference for the prevention and treatment of RSV.

    参考文献
    相似文献
    引证文献
引用本文

崔代迅,杨小慧,冯振卿.呼吸道合胞病毒疫苗及中和抗体研究进展[J].南京医科大学学报(自然科学版),2024,(12):1763-1772

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-04-18
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2024-12-16
  • 出版日期:
关闭